Pharmacogenomics: A Tool to Improve Medication Safety and Efficacy in Patients with Cystic Fibrosis

References

• Smith BA , ModiAC , QuittnerAL , WoodBL. Depressive symptoms in children with cystic fibrosis and parents and its effects on adherence to airway clearance. Pediatr. Pulmonol.45(8), 756–763 (2010).
   PubMed Web of Science ®Google Scholar
• Goetz D , RenCL. Review of cystic fibrosis. Pediatr. Ann.48(4), e154–e161 (2019).
   PubMed Web of Science ®Google Scholar
• Thorat T , McGarryLJ , BonafedeMMet al. Healthcare resource utilization and costs among children with cystic fibrosis in the United States. Pediatr. Pulmonol.56(9), 2833–2844 (2021).
   PubMed Web of Science ®Google Scholar
• Ramsey BW , DaviesJ , McElvaneyNGet al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med.365(18), 1663–1672 (2011).
   PubMed Web of Science ®Google Scholar
• Farrell PM , WhiteTB , RenCLet al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J. Pediatr.181S, S4–S15.e1 (2017).
   PubMed Web of Science ®Google Scholar
• Stallings VA , StarkLJ , RobinsonKAet al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J. Am. Diet Assoc.108(5), 832–839 (2008).
   PubMed Web of Science ®Google Scholar
• Sakon C , AliceaLA , PataccaH , BrownCD , SkaarTC , TillmanEM. Opportunity for pharmacogenomic testing in patients with cystic fibrosis. Pediatr. Pulmonol.57(4), 903–907 (2022).
   PubMed Web of Science ®Google Scholar
• Clinical Pharmacogenomics Implementation Consortium . What is CPIC? (2021). https://cpicpgx.org/
   Google Scholar
• Caudle KE , KleinTE , HoffmanJMet al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr. Drug Metab.15(2), 209–217 (2014).
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceuticals . Kalydeco Package Insert. Vertex Pharmaceuticals, MA, USA (2017)
   Google Scholar
• Vertex Pharmaceuticals . Orkambi Package Insert. Vertex Pharmaceuticals, MA, USA (2015).
   Google Scholar
• Vertex Pharmaceuticals . Symdeko Package Insert. Vertex Pharmaceuticals, MA, USA (2018).
   Google Scholar
• Vertex Pharmaceuticals . Trikafta Package Insert. Vertex Pharmaceuticals, MA, USA (2019).
   Google Scholar
• Van Der Meer R , WilmsEB , SturmR , HeijermanHGM. Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controls. J. Cyst. Fibros.20(5), e72–e76 (2021).
   PubMed Web of Science ®Google Scholar
• Robinson M , ByePT. Mucociliary clearance in cystic fibrosis. Pediatr. Pulmonol.33(4), 293–306 (2002).
   PubMed Web of Science ®Google Scholar
• Flume PA , MogayzelPJJr , RobinsonKAet al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med.180(9), 802–808 (2009).
   PubMed Web of Science ®Google Scholar
• Hurley MN , PrayleAP , FlumeP. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Cochrane Database Syst. Rev.2015(7), CD009730 (2015).
   PubMedGoogle Scholar
• Houwen RH , VanDer Doef HP , SermetIet al. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J. Pediatr. Gastroenterol. Nutr.50(1), 38–42 (2010).
   PubMed Web of Science ®Google Scholar
• Gelfond D , BorowitzD. Gastrointestinal complications of cystic fibrosis. Clin. Gastroenterol. Hepatol.11(4), 333–342; quiz e30-1 (2013).
   PubMed Web of Science ®Google Scholar
• Bell GC , CaudleKE , Whirl-CarrilloMet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin. Pharmacol. Ther.102(2), 213–218 (2017).
   PubMed Web of Science ®Google Scholar
• Lee AL , RawlingsS , BennettKA , ArmstrongD. Pain and its clinical associations in individuals with cystic fibrosis: a systematic review. Chron. Respir. Dis.13(2), 102–117 (2016).
   PubMed Web of Science ®Google Scholar
• Yaoli Y , TrinaH , ZubinM , AnitaL , CatherineD , AndrewTB. Attitudes of pain and opioids prescription practices in US cystic fibrosis centers. J. Cyst. Fibros.20(1), 127–132 (2021).
   PubMed Web of Science ®Google Scholar
• Burton SJ , HachemC , AbrahamJM. Luminal gastrointestinal manifestations of cystic fibrosis. Curr. Gastroenterol. Rep.23(3), 4 (2021).
   PubMedGoogle Scholar
• McCrory BE , HarperHN , McPhailGL. Use and incidence of adverse effects of proton pump inhibitors in patients with cystic fibrosis. Pharmacotherapy38(7), 725–729 (2018).
   PubMed Web of Science ®Google Scholar
• Lima JJ , FranciosiJP. Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs. Pharmacogenomics15(11), 1405–1416 (2014).
   PubMed Web of Science ®Google Scholar
• Lands LC , StanojevicS. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst. Rev.2007(4), CD001505 (2007).
   Google Scholar
• Theken KN , LeeCR , GongLet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin. Pharmacol. Ther.108(2), 191–200 (2020).
   PubMed Web of Science ®Google Scholar
• Grosser T , ThekenKN , FitzgeraldGA. Cyclooxygenase inhibition: pain, inflammation, and the cardiovascular system. Clin. Pharmacol. Ther.102(4), 611–622 (2017).
   PubMed Web of Science ®Google Scholar
• Quittner AL , Saez-FloresE , BartonJD. The psychological burden of cystic fibrosis. Curr. Opin. Pulm. Med.22(2), 187–191 (2016).
   PubMed Web of Science ®Google Scholar
• Hicks JK , BishopJR , SangkuhlKet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther.98(2), 127–134 (2015).
   PubMed Web of Science ®Google Scholar
• Hicks JK , SangkuhlK , SwenJJet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin. Pharmacol. Ther.102(1), 37–44 (2017).
   PubMed Web of Science ®Google Scholar
• Brown JT , BishopJR , SchneiderhanME. Using pharmacogenomics and therapeutic drug monitoring to guide drug selection and dosing in outpatient mental health comprehensive medication management. Ment. Health Clin.10(4), 254–258 (2020).
   PubMedGoogle Scholar
• Patel AR , PatelAR , SinghS , SinghS , KhawajaI. Treating allergic bronchopulmonary aspergillosis: a review. Cureus11(4), e4538 (2019).
   PubMed Web of Science ®Google Scholar
• Stevens DA , MossRB , KurupVPet al. Allergic bronchopulmonary aspergillosis in cystic fibrosis – state of the art: Cystic Fibrosis Foundation consensus conference. Clin. Infect. Dis.37(Suppl. 3), S225–S264 (2003).
   PubMedGoogle Scholar
• Moriyama B , ObengAO , BarbarinoJet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin. Pharmacol. Ther.102(1), 45–51 (2017).
   PubMed Web of Science ®Google Scholar
• Patel JN , HamadehIS , RobinsonMet al. Evaluation of CYP2C19 genotype-guided voriconazole prophylaxis after allogeneic hematopoietic cell transplant. Clin. Pharmacol. Ther.107(3), 571–579 (2020).
   PubMed Web of Science ®Google Scholar
• Bentley S , GuptaA , Balfour-LynnIM. Subtherapeutic itraconazole and voriconazole levels in children with cystic fibrosis. J. Cyst. Fibros.12(4), 418–419 (2013).
   PubMed Web of Science ®Google Scholar
• Birdwell KA , DeckerB , BarbarinoJMet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin. Pharmacol. Ther.98(1), 19–24 (2015).
   PubMed Web of Science ®Google Scholar
• Khush KK , CherikhWS , ChambersDCet al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult heart transplantation report – 2018; focus theme: multiorgan transplantation. J. Heart Lung Transplant.37(10), 1155–1168 (2018).
   PubMedGoogle Scholar
• Ciarleglio AE , MaC. The Daniel K Inouye College of Pharmacy scripts: precision medicine through the use of pharmacogenomics: current status and barriers to implementation. Hawaii J. Med. Public Health76(9), 265–269 (2017).
   PubMedGoogle Scholar
• Chan CY , ChuaBY , SubramaniamM , SuenEL , LeeJ. Clinicians’ perceptions of pharmacogenomics use in psychiatry. Pharmacogenomics18(6), 531–538 (2017).
   PubMed Web of Science ®Google Scholar
• Arwood MJ , ChumnumwatS , CavallariLH , NutescuEA , DuarteJD. Implementing pharmacogenomics at your institution: establishment and overcoming implementation challenges. Clin. Transl. Sci.9(5), 233–245 (2016).
   PubMed Web of Science ®Google Scholar
• Wang L , WeinshilboumR. Pharmacogenomics in practice. Clin. Pharmacol. Ther.106(5), 936–938 (2019).
   PubMed Web of Science ®Google Scholar
• Valgus J , WeitzelKW , PetersonJF , CronaDJ , FormeaCM. Current practices in the delivery of pharmacogenomics: impact of the recommendations of the Pharmacy Practice Model Summit. Am. J. Health Syst. Pharm.76(8), 521–529 (2019).
   PubMed Web of Science ®Google Scholar
• Frigon MP , BlackburnME , Dubois-BouchardC , GagnonAL , TardifS , TremblayK. Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients. Pharmacogenomics20(8), 589–598 (2019).
   PubMed Web of Science ®Google Scholar
• Kennedy MJ . Personalized medicines – are pharmacists ready for the challenge?Integr. Pharm. Res. Pract.7, 113–123 (2018).
   PubMed Web of Science ®Google Scholar
• Alexander KM , DivineHS , HannaCR , GokunY , FreemanPR. Implementation of personalized medicine services in community pharmacies: perceptions of independent community pharmacists. J. Am. Pharm. Assoc. (2003)54(5), 510–517; 5 p following 517 (2014).
   PubMed Web of Science ®Google Scholar
• Ferreri SP , GrecoAJ , MichaelsNMet al. Implementation of a pharmacogenomics service in a community pharmacy. J. Am. Pharm. Assoc. (2003)54(2), 172–180 (2014).
   PubMed Web of Science ®Google Scholar
• Reiss SM , AmericanPharmacists A. Integrating pharmacogenomics into pharmacy practice via medication therapy management. J. Am. Pharm. Assoc. (2003)51(6), e64–e74 (2011).
   PubMed Web of Science ®Google Scholar
• Zhu Y , MoriartyJP , SwansonKMet al. A model-based cost–effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? Genet. Med. 23(3), 461–470 (2021).
   PubMed Web of Science ®Google Scholar
• Van Westrhenen R , AitchisonKJ , Ingelman-SundbergM , JukicMM. Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going?Front. Psychiatry11, 94 (2020).
   PubMed Web of Science ®Google Scholar
• Chang A , NelsonR , BrixnerD. Advancing pharmacy practice by reducing gaps in pharmacogenetic education. Am. J. Health Syst. Pharm.76(5), 320–326 (2019).
   PubMed Web of Science ®Google Scholar
• Hippman C , NislowC. Pharmacogenomic testing: clinical evidence and implementation challenges. J. Pers. Med.9(3), 40 (2019).
   PubMed Web of Science ®Google Scholar
• De Sutter PJ , GasthuysE , Van BraeckelEet al. Pharmacokinetics in patients with cystic fibrosis: a systematic review of data published between 1999 and 2019. Clin. Pharmacokinet.59(12), 1551–1573 (2020).
   PubMed Web of Science ®Google Scholar
• Lenoir C , DaaliY , RollasonVet al. Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail. Clin. Pharmacol. Ther.109(6), 1668–1676 (2021).
   PubMed Web of Science ®Google Scholar
• Bain KT , SchwartzEJ , KnowltonOV , KnowltonCH , TurgeonJ. Implementation of a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE). J. Am. Pharm. Assoc. (2003)58(3), 281–289.e1 (2018).
   PubMed Web of Science ®Google Scholar
• Hicks JK , DunnenbergerHM , GumpperKF , HaidarCE , HoffmanJM. Integrating pharmacogenomics into electronic health records with clinical decision support. Am. J. Health Syst. Pharm.73(23), 1967–1976 (2016).
   PubMed Web of Science ®Google Scholar
• Cavallari LH , MasonDL. Cardiovascular pharmacogenomics – implications for patients with CKD. Adv. Chronic Kidney Dis.23(2), 82–90 (2016).
   PubMed Web of Science ®Google Scholar
• Cavallari LH , LeeCR , DuarteJDet al. Implementation of inpatient models of pharmacogenetics programs. Am. J. Health Syst. Pharm.73(23), 1944–1954 (2016).
   PubMed Web of Science ®Google Scholar
• Caraballo PJ , HodgeLS , BielinskiSJet al. Multidisciplinary model to implement pharmacogenomics at the point of care. Genet. Med.19(4), 421–429 (2017).
   PubMed Web of Science ®Google Scholar
• Hicks JK , StoweD , WillnerMAet al. Implementation of clinical pharmacogenomics within a large health system: from electronic health record decision support to consultation services. Pharmacotherapy36(8), 940–948 (2016).
   PubMed Web of Science ®Google Scholar